Loading...
XSHE
300653
Market cap420mUSD
Oct 09, Last price  
16.03CNY
1D
1.14%
1Q
10.70%
IPO
94.22%
Name

Yantai Zhenghai Bio-Tech Co Ltd

Chart & performance

D1W1MN
XSHE:300653 chart
P/E
34.55
P/S
7.82
EPS
0.46
Div yield, %
2.90%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
-1.87%
Revenues
364m
+0.25%
59,296,05777,376,969105,304,734128,132,520150,622,517182,782,114215,543,619279,807,036293,281,582400,175,251433,224,730433,224,730413,652,709363,225,350364,138,509
Net income
82m
-38.79%
8,515,11815,767,29533,660,49542,492,18445,470,11761,669,56285,815,070107,386,392118,333,989168,552,589185,436,805185,436,809190,957,573134,639,10882,410,131
CFO
97m
-35.80%
22,619,39534,383,49430,791,51245,739,64249,249,89765,473,42077,466,025103,477,376118,432,079166,134,014187,838,040180,477,811151,383,95597,190,675
Dividend
May 27, 20260.28 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Yantai Zhenghai Biotechnology Co., Ltd., founded in 2003 and based in Yantai, China, specializes in the innovation, manufacturing, and commercialization of regenerative medical materials across China. The company's product offerings include a bone repair material, which is a partially deproteinized substance derived from calf cancellous bone after undergoing a series of processes like decellularization and degreasing. It also provides membranes for oral cavity repair, specifically designed to address shallow soft tissue defects in the mouth. Under the "Heal-All" brand, it supplies biomembranes used in neurosurgical procedures to mend defects of the cerebral dura mater. Additionally, the "Heal-Full" brand encompasses skin repair membranes developed for treating wounds within the dermal layer.

Key people

Huanxiang Guo
Chairman of the Board · since 2024
Dong Qun
Vice Chairman of the Board · since 2015
Xing Yang
Deputy General Manager · since 2020
Donggang Zhang
Deputy General Manager, Staff Elected Director · since 2025
Kan Song
General Manager, Director · since 2024
Director · since 2025
Chao Zhang
Director · since 2018
Li Zhao
Chief Financial Officer, Finance Director, Deputy General Manager, Secretary of the Board, Director · since 2024
Jianghua Li
Independent Director · since 2024
Xiliang Song
Independent Director · since 2024
Independent Director · since 2024
IPO date
May 16, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT